Cannabidivarin (CBDV) and neuroprotection

by Duncan Fisher

November 18, 2022 - 2 min read

We wrote yesterday about one of the minor cannabinoids (cannabigerol, or ‘CBG’) as a newly-recognized neuroprotective agent, with an encouraging pharmaceutical development profile much like cannabidiol (CBD). There is another, in cannabidivarin (CBDV), a structural analogue of CBD, the same molecule but shortened by two methylene bridges. 

In vivo studies consistently report anti‐epileptic effects. CBDV, like CBD, is an agonist at TRPV1/2 andTRPA1 channels, and an antagonist atTRPM8 channels, which may explain this. But, because it is known that CBDV does not affect neurotrophic levels or epilepsy‐related gene expression, its protective effects are independent of these pathways. Plasma and brain concentration after oral treatment varies between experimental animal species, for reasons not known, bringing into question its pharmacokinetic properties in eventual human trials. Long‐term tolerability of CBDV as an anti‐epileptic agent in humans is an unknown at this point as well. 

Short-term anti‐convulsant efficacy has been trialed in a phase IIa human study of the experimental, CBDV-containing drug GWP42006. Focal seizures were not adequately controlled compared to placebo controls in that study. There is uncertainty about whether the dose levels were appropriate, however. The study designers have also observed that there was a surprisingly high response in the placebo group. Dose-determination is the function of phase II trials. Much work remains to be done as CBDV moves into clinical study. Given what appears to be encouraging preclinical evidence, however, this work is very much warranted. 


DiolPure products contain PureForm CBD™ transformed from aromatic terpenes for pharmaceutical-grade purity. PureForm CBD™ is bioidentical to CBD extracted from hemp and cannabis, but free of any residual cannabinoids like THC or impurities or chemicals that can associate with traditional plant-derived production processes. 

The foregoing is a report on trends and developments in cannabinoid industry research. No product description herein is intended as a recommendation for diagnosis, treatment, cure or prevention of any disease or syndrome. 

Beyond glaucoma: Cannabinoids in ophthalmology

Beyond glaucoma: Cannabinoids in ophthalmology

Cannabinoids appear to have therapeutic potential in glaucoma. Beyond this, there may be further promise in ophthalmology.
Read More

December 05, 2022 1 min read

The endocannabinoid system and bone disease

The endocannabinoid system and bone disease

Stimulation of the endocannabinoid system modulates bone formation and bone resorption. There may be a role one day for targeted drugs in osteoporosis and some forms of bone cancer. 
Read More

December 02, 2022 1 min read

Sex differences, endocannabinoids, and pain

Sex differences, endocannabinoids, and pain

Sex differences in pain perception and analgesia is a burgeoning research field overall. What about cannabinoid analgesia specifically? 
Read More

December 01, 2022 2 min read

Follow us on Instagram

Net Orders Checkout

Item Price Qty Total
Subtotal $ 0.00

Shipping Address

Shipping Methods